Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Total Income: ₹406.30 crores, down from ₹535.90 crores in previous quarter and also down by 12.5 percent on the YoY basis.
-
Total Expenses: ₹320.5 crores, down from ₹364 crores in previous quarter and also down by 10.3 percent from the same quarter, last year.
-
Profit Before Tax (PBT): ₹94.50 crores (down from ₹165.60 crores)
-
Profit After Tax (PAT): ₹69.50 crores, down from ₹172 crores in the previous quarter and also down by 32.4 percent on the YoY basis.
-
EBIT (Earnings Before Interest & Tax): ₹94.50 crores
-
EBIT Margin: Approximately 22.77%
-
Net Profit Margin: Approximately 17.24%
-
Basic EPS: ₹30.22, a decline of 32.7 percent on the YoY basis
Management Commentary & Strategic Highlights:
-
Sanofi India reported a 32% decline in profit for Q1 FY26 compared to Q1 FY25, mainly due to lower sales and higher input costs.
-
The company continues its focus on strengthening its product portfolio, especially in specialty care including diabetes and cardiovascular medicines.
-
Sanofi India’s strategic focus remains on innovation, expanding market share in niche segments, and improving operational efficiencies.
-
Emphasis on increasing footprint in emerging therapies and making investments in R&D and marketing.
-
Management highlighted navigating competitive pressures and economic headwinds while staying committed to growth and sustainable profitability.
Q4 FY25 Earnings Results
-
Total Income: ₹536 crores, up by 4.89 percent on the YoY basis.
-
Total Expenses: ₹364 crores, down by 2.6 percent on the YoY basis.
-
Profit After Tax (PAT): ₹120 crores, down by 12.4 percent from the same quarter, last year
-
EBIT: ₹165.60 crores
-
EBIT Margin: Approximately 30.71%
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.